(Q47573495)

4 February 2018

title

Towards a biological staging model for operable non-small cell lung cancer (English)

1 reference

4 February 2018

author name string

O'Byrne KJ

1

1 reference

4 February 2018

Cox G

2

1 reference

4 February 2018

Swinson D

3

1 reference

4 February 2018

Richardson D

4

1 reference

4 February 2018

Edwards JG

5

1 reference

4 February 2018

Lolljee J

6

1 reference

4 February 2018

Andi A

7

1 reference

4 February 2018

Koukourakis MI

8

1 reference

4 February 2018

Giatromanolaki A

9

1 reference

4 February 2018

Gatter K

10

1 reference

4 February 2018

Harris AL

11

1 reference

4 February 2018

Waller D

12

1 reference

4 February 2018

Jones JL

13

1 reference

4 February 2018

publication date

1 December 2001

1 reference

4 February 2018

published in

Lung Cancer

1 reference

4 February 2018

volume

34 Suppl 2

1 reference

4 February 2018

page(s)

S83-9

1 reference

4 February 2018

Revisions in the International System for Staging Lung Cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Angiogenesis and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Immunocytochemical markers in stage I lung cancer: relevance to prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Matrix metalloproteinases in tumour invasion and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

A biological staging model for operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Antiangiogenesis for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Oncogenic targets of beta-catenin-mediated transcription in molecular pathogenesis of intestinal polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Nuclear beta catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Expression of VEGF in routinely fixed material using a new monoclonal

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Thymidine phosphorylase is angiogenic and promotes tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Prognostic significance of angiogenesis in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

HIF-1: using two hands to flip the angiogenic switch

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Causes and consequences of hypoxia and acidity in tumors – Novartis Foundation symposium

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900352-X

7 January 2021

10.1016/S0169-5002(01)00352-X

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018